相关临床试验
303
12 进行中
药物批准
12
批准总数
监管机构
2
监管机构数
成立时间
1941
进行中（未招募）
2
0.7%
已完成
218
72.0%
尚未招募
10
3.3%
招募中
14
4.6%
终止
1
0.3%
Unknown
58
19.1%
- DelveInsight's 2025 pipeline analysis reveals over 10 companies developing 12+ therapies for gastroesophageal reflux disease, with novel potassium-competitive acid blockers leading innovation. - Onconic Therapeutics' Zastaprazan has entered Phase III trials for reflux esophagitis, representing a new P-CAB class that offers longer duration of action compared to traditional proton pump inhibitors. - Cinclus Pharma's X842, a prodrug of linaprazan, is advancing through Phase II development with potential to heal esophageal injuries more effectively than current pharmaceutical therapies. - The GERD market addresses a significant unmet need, with the condition affecting 20% of the US population and creating substantial economic burden through direct and indirect costs.
- DelveInsight's 2025 report reveals over 200 companies are actively developing more than 200 pipeline therapies for diabetes treatment, indicating a highly competitive and innovative landscape. - Several promising late-stage candidates are advancing through Phase III trials, including Cadisegliatin (vTv Therapeutics) for type 1 diabetes and Insulin efsitora alfa (Eli Lilly) as a once-weekly basal insulin. - Recent clinical trial announcements from major pharmaceutical companies demonstrate continued investment in diabetes research, with studies comparing novel formulations and combination therapies. - The pipeline encompasses diverse therapeutic approaches including liver-selective glucokinase activators, ultra-rapid-acting insulin analogs, and oral GLP-1 receptor agonists targeting different aspects of diabetes management.
- DelveInsight's latest report reveals a robust pipeline for androgenetic alopecia with 80+ companies developing 100+ therapeutic candidates across various clinical stages. - Key emerging treatments include KX-826 from Kintor Pharma and Clascoterone from Cassiopea, which could significantly expand options beyond the current FDA-approved minoxidil and finasteride. - Recent clinical trial results from companies like Veradermics, Chong Kun Dang, and Pelage Pharmaceuticals demonstrate increasing R&D investment in addressing this common condition affecting up to 50% of both men and women.
- Novartis has signed a $1.3 billion licensing agreement with Korean biotech Chong Kun Dang Pharmaceutical for CKD-510, an HDAC6 inhibitor with FDA orphan drug designation for Charcot-Marie-Tooth disease. - The deal includes an $80 million upfront payment plus $1.2 billion in potential milestone payments, with Novartis gaining exclusive global rights to develop and commercialize the drug outside Korea. - This acquisition follows Novartis' recent procurement of DTX-1252, another CMT1A therapeutic candidate, signaling the company's strategic expansion into rare neurological disease treatments.
